Abstract Vascular endothelial growth factor (VEGF) plays an important role in the development of Breast Cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23 % of the total cancer cases and 14 % of the cancer deaths [1] . It is estimated that presently nearly one million new cancer cases are being detected annually in the country [2] . Presently, 75,000 new cases of breast cancer occur in Indian women every year. The breast is the second most common site of cancer in women after the cervix uteri [3] . Results from experimental studies suggest that tumor progression and metastasis in breast cancer are angiogenesis dependent [4] .
A key mediator in neoangiogenesis is vascular endothelial growth factor (VEGF) as it stimulates endothelial cell proliferation and migration, and increases vascular permeability; [5, 6] it is therefore regarded as a marker of tumor invasion and metastasis [7] . The VEGF gene is located on chromosome 6p21.3 and consists of eight exons that exhibit alternate splicing to form a family of proteins [8] . Purified VEGF is an approximately 46-kDa protein and it dissociates upon reduction into two apparently identical 23-kDa subunits [9] .
There is considerable variation between individuals in VEGF expression, and analysis of the 5 0 flanking region of the gene has shown the presence of many polymorphisms [10] [11] [12] . G ? C transition at ?405 in the 5 0 -untranslated region has been implicated in a number of diseases, especially those with angiogenic basis [13, 14] . VEGF protein production was found to be associated with ?405 polymorphism in healthy subjects [12] . Association has been reported in case-control studies between VEGF polymorphisms and diseases such as diabetic retinopathy, [13] ovarian cancer, [15] and endometriosis [16] .
Analysis of the VEGF gene promoter region revealed a single major transcription start, which lies near a cluster of potential Spl factor binding sites. The promoter region also contains several potential binding sites for the transcription factors AP-1 and AP-2 [9] . The -1154G[A transition lies in the promoter region of the VEGF gene [17] . The -1154AA and GA genotypes were associated with low VEGF expression in lung cancer [18] . Jacobs et al. [19] have reported that one or two copies of -1154A allele resulted in lower risk of invasive breast cancer compared with zero-copy carriers. In another study by Schneider et al. [20] among American population, showed an increase in overall survival in breast cancer patients that carry -1154G[A polymorphism. In contrast carriers of 1154GG genotypes had increased VEGF secretion in human peripheral blood mononuclear cells compared with carriage of a rare allele [21, 22] .
In spite of the importance of angiogenesis in Breast cancer, there have been no published studies on the association of VEGF gene polymorphism and Breast cancer among Indians. This case control study was undertaken to study the prevalence of VEGF polymorphisms among Breast cancer patients and its association on the prognosis of Breast cancer. We also studied VEGF plasma levels in 200 healthy subjects and 200 patients to assess possible functional relevance of the VEGF polymorphisms.
Materials and Methods

Study Population
Histologically confirmed cases of Breast cancer samples were obtained from 200 patients registered (2008) (2009) The study protocol was approved by the Institutional Ethical Committee and Informed consent was obtained from the patients/relatives of the subjects under study. All the participants of the study belonged to the same ethnic group.
Blood Collection and DNA Extraction About 5 ml of blood was collected from each subject after an overnight fast by routine venipuncture. The blood sample was then distributed into different tubes for the assays of various biochemical parameters. DNA for PCR-RFLP analysis was extracted from leukocytes isolated from whole blood by using DNA extraction kit (Genei). 
Genotyping of VEGF Polymorphisms
Genotyping of the ?405G[C polymorphisms in the 5 0 UTR of the VEGF gene was determined by PCR/RFLP analysis. The method described by Buraczynska et al. [23] was used for the detection of ?405G[C polymorphism. PCR was carried out in a total volume of 30 ll, containing 200 ng genomic DNA, 1.5 lmol of each primer (Sigma, USA), IX Taq polymerase buffer (1.5 mM MgCl2) and 1 U of Taq DNA polymerase (Bangalore Genie, India). For the ?405G[C polymorphism the forward and reverse primers were 5 0 -ATTTATTTTTGCTTGCCATT-3 0 and 5 0 -GTCTGTCTGTCTGTCCGTCA-3 0 respectively. PCR amplification was performed in a programmable thermal cycler gradient PCR system (Eppendorf AG, Hamburg, Germany). The PCR product was digested with the BsmFI restriction endonuclease. (New England Biolabs, USA) at 65°C overnight for the ?405G[C polymorphism, separated by 2 % agarose gel electrophoresis, and identified using ethidium bromide staining. For the VEGF ?405 polymorphism the uncut fragment was 304 bp (C allele) and digestion products were 193 and 111 bp (G allele).
The method described by Han et al. [24] was used for the detection of -1154G[A polymorphisms. For the -1154G[A polymorphism the forward and reverse 
Plasma VEGF levels were determined among 200 patients using commercially available enzyme-linked immunoassay (ELISA) (Quantikine, R&D Systems Minneapolis, MN). The assay exhibits no significant cross-reactivity with other angiogenesis factors and has a sensitivity of 9.0 pg/ml. Optical density was measured at 450 nm using a microtitre plate reader (TECAN ELISA READER). Sample concentrations were assessed using a 1:2 dilution of a standard stock of VEGF (2,000 pg/ml) to 174, 1000, 500, 250, 125, 62.5, and 31.2 pg/ml.
Quantitation of Plasma VEGF Levels Using ELISA Assay Aliquot 0.1 ml per well of the 2000, 1000, 500, 250, 125, 62.5, 31.2 pg/ml human VEGF standard solutions into the precoated 96-well plate. Add 0.1 ml of the sample diluent buffer into the control well (Zero well). Add 0.1 ml of each properly diluted sample of human sera, plasma, body fluids, tissue lysates or cell culture supernatants to each empty well. Seal the plate with the cover and incubate at RT for 2 h. Remove the cover, discard plate content and wash the plate three times with wash buffer. Add 0.1 ml of biotinylated anti-human VEGF antibody working solution into each well and incubate the plate at RT for 2 h. Wash the plate three times with wash buffer. Add 0.2 ml of prepared Substrate solution into each well and incubate the plate at RT for 25 min. Wash plate 3 t with times with wash buffer. Add 0.2 ml of prepared stop solution into each well. The color changes into yellow immediately. Absorbance was measured at 450 nm in a microplate reader. Statistical Analysis OR and 95 % CI were estimated as a measure of association between the genotype and Breast cancer. The genotypic distribution amongst subjects was tested for HardyWeinberg equilibrium using Fisher's exact test. Results on continuous measurements were presented on Mean ± SD (Min-Max) and results on categorical measurements were presented in Number (%). ROC curve analysis was performed to find the cut-off value VEGF-ELISA and Diagnostic value. Logistic regression analysis has been carried to assess the association of predictors of elevated VGEF (pg/ml) in cases. All statistical analysis was performed using SPSS 16.0. Statistical significance was assessed with a cut-off level of P \ 0.05.
Results
The patients characteristics are described in Table 1 . Clinically healthy individuals were used as controls. Amongst both cases and controls, the genotypic distributions of the individual SNPs (?405G[C,-1154G[A) did not significantly deviate from the Hardy-Weinberg equilibrium (Tables 2, 3 ). The ?405 Genotype frequencies amongst the 200 cases were GG = 44.5 %, GC = 44 % and CC = 11.5 %. The ?405 Genotype frequencies amongst the 200 controls were GG = 42.5 %, GC = 44.5 % and CC = 13 %. PCR product of ?405G[C SNP has 304base pairs. For the VEGF ?405 polymorphism the uncut fragment was 304 bp (C allele, mutant allele) and digestion products were 193 and 111 bp (G allele, wild type) (Fig. 1a, b) (Fig. 2a, b) .
VEGF Sequence Variants and Breast Cancer
We examined the effect of the VEGF ?405G[C and -1154G[A polymorphisms in relation to Breast cancer. In the present study a significant association was observed between VEGF polymorphism and nodal status. ?405GC,-1154GA & AA genotypes were significantly less in node positive patients while carriers of the 405CC allele tended to have more node positive tumors than carriers of other genotype, which was significantly associated (0.004**). No other significant associations was found between the simultaneous carriage of the ?405CC & -1154AA homozygous genotypes and tumor characteristics such as TNM stage, Grade, ER/PR status of the patients at the time of diagnosis. The results are shown in Table 4 .
Plasma VEGF levels ranged from 31 to 876 pg/ml among breast cancer patients and among controls a range of non detectable level, (i.e.\9 pg/ml) to 136.0 pg/ml. Mean VEGF level was significantly elevated in cases compared to control (126.58 vs. 71.76 pg/ml, P \ 0.001) ( Table 5 ). Statistical cut off was determined using ROC curve ( Fig. 3; Table 6 ). Baseline concentrations of plasma VEGF were elevated (C123 pg/ml) in 52 % (103) of the 200 evaluable patients.
Next, we studied VEGF plasma levels and VEGF genotypes in Breast cancer patients and healthy subjects to assess possible functional relevance of the VEGF polymorphisms. The highest production was observed for the Results are mean ± SD for VEGF pg/ml ** Strongly significant (P value: P B 0.01) 405GG genotype, the intermediate production for the 405GC genotype, and the lowest production was observed for the 405CC genotype (Table 7) . For 1154G[A polymorphism, the highest production was observed for the GG genotype, the intermediate production for the GA genotype, and the lowest production was observed for the AA genotype Patients with -1154AA allele were showing lowest VEGF production suggesting a protective role of this allele but this was not statistically significant (P = 0.681) ( Table 8) . By Logistic regression analysis we found that ?405GG & -1154GG genotypes were associated with higher levels of VEGF (Table 9) .
Discussion
Several studies have evaluated the association of VEGF polymorphisms with breast cancer risk [25] [26] [27] . The results, however, have been inconsistent. Studies have shown that several polymorphisms were associated with the production of the VEGF protein, and suggested that the regulation of VEGF expression occurs primarily at a transcriptional level [28] . The ?405G[C transition lies in 5 0 untranslated region of the VEGF gene [17] . Watson et al. [12] reported that a G allele at position ?405, which probably lies within the myeloid zinc finger protein (MZF1) binding site, affects transcriptional activity and increases VEGF production in peripheral blood mononuclear cells in response to lipopolysaccharide. We also observed that the ?405C haplotype, which is associated with lower promoter activity, was more common in controls than in affected women. In contrast Awata et al. [13] reported that individuals with the ?405CC genotype had a higher fasting serum VEGF level than those with other genotypes, and that they carried an increased risk of diabetic retinopathy. Stevens et al. [29] also reported that haplotype ?405G has a higher promoter activity than haplotype ?405C.
We have found that VEGF levels were significantly increased (P \ 0.001) in patients compared to controls. The highest production was observed for the 405GG genotype, and the lowest for 405CC genotype ( Table 7) . The sensitivity of plasma VEGF in detecting breast cancer was 51.76 %, and the specificity was 89 % using a VEGF level of 123 pg/ml as the cutoff value. With the use of a highly sensitive enzyme immunoassay, we found that most of the primary invasive breast cancers had detectable concentrations of VEGF protein.
Several studies analyzed the effect of -1154G[A polymorphism among Breast cancer patients. A smaller study from the UK, including 144 cases and 263 controls, evaluated the effect of SNPs in the promoter regions of various cytokines, including the VEGF -1154G[A transition, on risk and prognosis of breast cancer [27] . Schneider et al. [30] in a case control study evaluated the effect -1154G[A polymorphism in cancer patients reported an improved median overall survival in patients with VEGF-1154AA genotypes. In conclusion VEGF -1154G[A had no relation with overall risk of breast cancer, [19, 26, 27, 30] however the G allele was related with increased risk of invasive disease [19, 27, 30] . The VEGF polymorphism at position -1154 located within the promoter region has been linked to alterations in VEGF level [21, 22] . Pander et al. [31] reported that the variant allele for -1154G[A results in lower VEGF expression. A case-control study, with 571 breast cancer patients, evaluated the role of the germline VEGF -1154G[A SNP in German individuals, found that -1154GG has been associated with a higher VEGF production [26] .
In our study, for 1154G[A polymorphism, the highest production was observed for the GG genotype, and patients with -1154A allele were showing lowest VEGF production (Table 8 ). -1154GA, AA genotypes were significantly less in node positive patients showing an OR 0.14 & 0.014 respectively (Table 4) .
In the present study, the genotype distribution of the ?405G[C, -1154G[A VEGF gene polymorphism was not significantly different between the cases and the controls. For ?405G[C and 1154G[A, polymorphism, the highest production of plasma VEGF was observed for the GG genotype. 1154GA, AA genotypes were significantly less in node positive cases. Furthermore patients with -1154A allele were showing lowest VEGF production suggesting a protective role of this allele but this was not statistically significant. However, further studies on larger populations may be necessary to confirm these observations.
